This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rennels, M. B.
Right arrow Articles by Kimura, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rennels, M. B.
Right arrow Articles by Kimura, A.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 101 No. 4 April 1998, pp. 604-611

Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants

Received Apr 24, 1997; accepted Aug 1, 1997.

Margaret B. Rennels*, Kathryn M. EdwardsDagger , Harry L. Keyserling§, Keith S. Reisingerparallel , Deborah A. Hogerman, Dace V. Madore, Ih Chang, Peter R. Paradiso, Frank J. Malinoski, and Alan Kimura

From the * Center for Vaccine Development and Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland; the Dagger  Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; the § Division of Infectious Diseases, Epidemiology, and Immunology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; parallel  Pittsburgh Pediatric Research, Pittsburgh, Pennsylvania; and  Wyeth-Lederle Vaccines and Pediatrics, West Henrietta, New York.

Objective.  To determine the safety and immunogenicity of heptavalent pneumococcal saccharide vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) individually conjugated to CRM197 (PNCRM7), administered at 2, 4, 6, and 12 to 15 months of age.

Design.  Two hundred twelve healthy 2-month-old infants were equally randomized to receive four consecutive doses of PNCRM7 or an investigational meningococcal group C conjugate vaccine, which served as a control. Concomitantly administered routine vaccines were oral polio vaccine and combined diphtheria toxoid, tetanus toxoid, and whole cell pertussis vaccine/Haemophilus influenzae type b vaccine consisting of capsular oligosaccharides conjugated to CRM197 (DTP/HbOC) at 2, 4, and 6 months, and either measles-mumps-rubella vaccine or HbOC at 12 to 15 months. Active safety surveillance was conducted for 3 days after each dose. Antibody concentrations to each of the 7 pneumococcal serotypes were measured by enzyme-linked immunosorbent assay prevaccination, after doses two and three, prebooster, and postbooster.

Results.  Significantly fewer children experienced local reactions at the PNCRM7 injection site than at the DTP/HbOC site. There was no increase in the incidence or severity of local reactions at the PNCRM7 site with increasing doses of vaccine. Mild to moderate postvaccination fever was common in both the PNCRM7 and control vaccine groups, however DTP/HbOC was administered concurrently. All 7 vaccine serotypes were immunogenic. The kinetics of the immune responses were serotype-specific. After three doses of PNCRM7, between 92% to 100% of children had >= 0.15 µg/mL of antibody, and 51% to 90% achieved a level of >= 1 µg/mL against specific serotypes. A booster dose of PNCRM7 resulted in a brisk anamnestic response to all 7 vaccine serotypes, demonstrating effective stimulation of T-cell memory by the primary series of vaccinations.

Conclusion.  Primary immunization followed by a booster dose of PNCRM7 seemed to be acceptably safe and resulted in significant rises in antibody to all 7 serotypes.

Implications.  Studies to assess vaccine efficacy of PNCRM7 for prevention of systemic disease, nasopharyngeal colonization, and acute otitis media are in progress. If PNCRM7 proves to be protective, there is the potential to prevent up to 85% of invasive pneumococcal disease occurring in US children.

Key words: vaccine, pediatric, pneumococcal.




This article has been cited by other articles:


Home page
 CVIHome page
E. A. Clutterbuck, S. Oh, M. Hamaluba, S. Westcar, P. C. L. Beverley, and A. J. Pollard
Serotype-Specific and Age-Dependent Generation of Pneumococcal Polysaccharide-Specific Memory B-Cell and Antibody Responses to Immunization with a Pneumococcal Conjugate Vaccine
Clin. Vaccine Immunol., February 1, 2008; 15(2): 182 - 193.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
P. Balmer, R. Borrow, J. Findlow, R. Warrington, S. Frankland, P. Waight, R. George, N. Andrews, and E. Miller
Age-Stratified Prevalences of Pneumococcal-Serotype-Specific Immunoglobulin G in England and Their Relationship to the Serotype-Specific Incidence of Invasive Pneumococcal Disease Prior to the Introduction of the Pneumococcal 7-Valent Conjugate Vaccine
Clin. Vaccine Immunol., November 1, 2007; 14(11): 1442 - 1450.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
N. Ekstrom, M. Vakevainen, J. Verho, T. Kilpi, H. Kayhty, and the FinOM Study Group
Functional Antibodies Elicited by Two Heptavalent Pneumococcal Conjugate Vaccines in the Finnish Otitis Media Vaccine Trial
Infect. Immun., April 1, 2007; 75(4): 1794 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Meisel, L. Kuypers, U. Dirksen, R. Schubert, B. Gruhn, G. Strauss, K. Beutel, A. H. Groll, U. Duffner, R. Blutters-Sawatzki, et al.
Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation
Blood, March 15, 2007; 109(6): 2322 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
M. Abuelreish, A. Subedar, T. Chiu, P. Wludyka, and M. Rathore
Increase in Invasive Pneumococcal Disease in Children Associated With Shortage of Heptavalent Pneumococcal Conjugate Vaccine
Clinical Pediatrics, January 1, 2007; 46(1): 45 - 52.
[Abstract] [PDF]

Home page
 CVIHome page
R. L. Burton and M. H. Nahm
Development and Validation of a Fourfold Multiplexed Opsonization Assay (MOPA4) for Pneumococcal Antibodies.
Clin. Vaccine Immunol., September 1, 2006; 13(9): 1004 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. O. Wasfy, G. Pimentel, M. Abdel-Maksoud, K. L. Russell, C. P. Barrozo, J. D. Klena, K. Earhart, and R. Hajjeh
Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae causing meningitis in Egypt, 1998-2003
J. Antimicrob. Chemother., June 1, 2005; 55(6): 958 - 964.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
B. T. Hu, X. Yu, T. R. Jones, C. Kirch, S. Harris, S. W. Hildreth, D. V. Madore, and S. A. Quataert
Approach to Validating an Opsonophagocytic Assay for Streptococcus pneumoniae
Clin. Vaccine Immunol., February 1, 2005; 12(2): 287 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
N. Ekstrom, H. Ahman, J. Verho, J. Jokinen, M. Vakevainen, T. Kilpi, H. Kayhty, and the Finnish Otitis Media Study Group
Kinetics and Avidity of Antibodies Evoked by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial
Infect. Immun., January 1, 2005; 73(1): 369 - 377.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
D. Tarrago, J. Casal, J. Ruiz-Contreras, J. T. Ramos, P. Rojo, H. Snippe, and W. T. M. Jansen
Assessment of Antibody Response Elicited by a 7-valent Pneumococcal Conjugate Vaccine in Pediatric Human Immunodeficiency Virus Infection
Clin. Vaccine Immunol., January 1, 2005; 12(1): 165 - 170.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
D. J. Sikkema, N. A. Ziembiec, T. R. Jones, S. W. Hildreth, D. V. Madore, and S. A. Quataert
Assignment of Weight-Based Immunoglobulin G1 (IgG1) and IgG2 Units in Antipneumococcal Reference Serum Lot 89-S(F) for Pneumococcal Polysaccharide Serotypes 1, 4, 5, 7F, 9V, and 18C
Clin. Vaccine Immunol., January 1, 2005; 12(1): 218 - 223.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
S. A. Quataert, K. Rittenhouse-Olson, C. S. Kirch, B. Hu, S. Secor, N. Strong, and D. V. Madore
Assignment of Weight-Based Antibody Units for 13 Serotypes to a Human Antipneumococcal Standard Reference Serum, Lot 89-S(F)
Clin. Vaccine Immunol., November 1, 2004; 11(6): 1064 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
K. L. O'Brien and M. Santosham
Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases
Am. J. Epidemiol., April 1, 2004; 159(7): 634 - 644.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Latz, J. Franko, D. T. Golenbock, and J. R. Schreiber
Haemophilus influenzae Type b-Outer Membrane Protein Complex Glycoconjugate Vaccine Induces Cytokine Production by Engaging Human Toll-Like Receptor 2 (TLR2) and Requires the Presence of TLR2 for Optimal Immunogenicity
J. Immunol., February 15, 2004; 172(4): 2431 - 2438.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
T. L. McCool, J. R. Schreiber, and N. S. Greenspan
Genetic Variation Influences the B-Cell Response to Immunization with a Pneumococcal Polysaccharide Conjugate Vaccine
Infect. Immun., September 1, 2003; 71(9): 5402 - 5406.
[Abstract] [Full Text] [PDF]

Home page
 J Am Board Fam MedHome page
M. M. Davis, S. M. Ndiaye, G. L. Freed, and S. J. Clark
One-Year Uptake of Pneumococcal Conjugate Vaccine: A National Survey of Family Physicians and Pediatricians
J Am Board Fam Med, September 1, 2003; 16(5): 363 - 371.
[Abstract] [Full Text]

Home page
 CVIHome page
C. M. Wernette, C. E. Frasch, D. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S. A. Quataert, S. Hildreth, D. J. Sikkema, et al.
Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal Polysaccharides
Clin. Vaccine Immunol., July 1, 2003; 10(4): 514 - 519.
[Full Text] [PDF]

Home page
 CVIHome page
K. H. Kim, J. Yu, and M. H. Nahm
Efficiency of a Pneumococcal Opsonophagocytic Killing Assay Improved by Multiplexing and by Coloring Colonies
Clin. Vaccine Immunol., July 1, 2003; 10(4): 616 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
E. G. Leonard, D. H. Canaday, C. V. Harding, and J. R. Schreiber
Antigen Processing of the Heptavalent Pneumococcal Conjugate Vaccine Carrier Protein CRM197 Differs Depending on the Serotype of the Attached Polysaccharide
Infect. Immun., July 1, 2003; 71(7): 4186 - 4189.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. Nachman, S. Kim, J. King, E. J. Abrams, D. Margolis, A. Petru, W. Shearer, E. Smith, J. Moye, S. Blanchard, et al.
Safety and Immunogenicity of a Heptavalent Pneumococcal Conjugate Vaccine in Infants With Human Immunodeficiency Virus Type 1 Infection
Pediatrics, July 1, 2003; 112(1): 66 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. Zlotkin, S. Chilmonczyk, M. Eyngor, A. Hurvitz, C. Ghittino, and A. Eldar
Trojan Horse Effect: Phagocyte-Mediated Streptococcus iniae Infection of Fish
Infect. Immun., May 1, 2003; 71(5): 2318 - 2325.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. I. Pelton and J. O. Klein
The Future of Pneumococcal Conjugate Vaccines for Prevention of Pneumococcal Diseases in Infants and Children
Pediatrics, October 1, 2002; 110(4): 805 - 814.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Flamaing, J. Verhaegen, and W. E. Peetermans
Streptococcus pneumoniae bacteraemia in Belgium: differential characteristics in children and the elderly population and implications for vaccine use
J. Antimicrob. Chemother., July 1, 2002; 50(1): 43 - 50.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
A. Hoberman, C. D. Marchant, S. L. Kaplan, and S. Feldman
Treatment of Acute Otitis Media Consensus Recommendations
Clinical Pediatrics, July 1, 2002; 41(6): 373 - 390.
[Abstract] [PDF]

Home page
 J Med MicrobiolHome page
S. OBARO and R. ADEGBOLA
The pneumococcus: carriage, disease and conjugate vaccines
J. Med. Microbiol., February 1, 2002; 51(2): 98 - 104.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. S. Giebink
The Prevention of Pneumococcal Disease in Children
N. Engl. J. Med., October 18, 2001; 345(16): 1177 - 1183.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
P. H. Dennehy
Active Immunization in the United States: Developments over the Past Decade
Clin. Microbiol. Rev., October 1, 2001; 14(4): 872 - 908.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
T. Lahiri and D. A. Waltz
Preimmunization Anti-Pneumococcal Antibody Levels Are Protective in a Majority of Patients With Cystic Fibrosis
Pediatrics, October 1, 2001; 108(4): e62 - 62.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
E. R. Alpern, E. A. Alessandrini, K. L. McGowan, L. M. Bell, and K. N. Shaw
Serotype Prevalence of Occult Pneumococcal Bacteremia
Pediatrics, August 1, 2001; 108 (2): e23 - e23.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S Choo and A Finn
Current topic: New pneumococcal vaccines for children
Arch. Dis. Child., April 1, 2001; 84(4): 289 - 294.
[Full Text]

Home page
 CVIHome page
W. T. M. Jansen, M. Vakevainen-Anttila, H. Kayhty, M. Nahm, N. Bakker, J. Verhoef, H. Snippe, and A. F. M. Verheul
Comparison of a Classical Phagocytosis Assay and a Flow Cytometry Assay for Assessment of the Phagocytic Capacity of Sera from Adults Vaccinated with a Pneumococcal Conjugate Vaccine
Clin. Vaccine Immunol., March 1, 2001; 8(2): 245 - 250.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
N. F. Concepcion and C. E. Frasch
Pneumococcal Type 22F Polysaccharide Absorption Improves the Specificity of a Pneumococcal-Polysaccharide Enzyme-Linked Immunosorbent Assay
Clin. Vaccine Immunol., March 1, 2001; 8(2): 266 - 272.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
K. L. O'Brien, M. A. Bronsdon, R. Dagan, P. Yagupsky, J. Janco, J. Elliott, C. G. Whitney, Y.-H. Yang, L.-G. E. Robinson, B. Schwartz, et al.
Evaluation of a Medium (STGG) for Transport and Optimal Recovery of Streptococcus pneumoniae from Nasopharyngeal Secretions Collected during Field Studies
J. Clin. Microbiol., March 1, 2001; 39(3): 1021 - 1024.
[Abstract] [Full Text]

Home page
 NEJMHome page
J. Eskola, T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Kayhty, P. Karma, R. Kohberger, et al.
Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media
N. Engl. J. Med., February 8, 2001; 344(6): 403 - 409.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
W. T. M. Jansen, S. Hogenboom, M. J. L. Thijssen, J. P. Kamerling, J. F. G. Vliegenthart, J. Verhoef, H. Snippe, and A. F. M. Verheul
Synthetic 6B Di-, Tri-, and Tetrasaccharide-Protein Conjugates Contain Pneumococcal Type 6A and 6B Common and 6B- Specific Epitopes That Elicit Protective Antibodies in Mice
Infect. Immun., February 1, 2001; 69(2): 787 - 793.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
E. N. Miyaji, R. P. Mazzantini, W. O. Dias, A. L. T. O. Nascimento, R. Marcovistz, D. S. Matos, I. Raw, N. Winter, B. Gicquel, R. Rappuoli, et al.
Induction of Neutralizing Antibodies against Diphtheria Toxin by Priming with Recombinant Mycobacterium bovis BCG Expressing CRM197, a Mutant Diphtheria Toxin
Infect. Immun., February 1, 2001; 69(2): 869 - 874.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
L. P. Jetté, G. Delage, L. Ringuette, R. Allard, P. De Wals, F. Lamothe, V. Loo, and the Pneumococcus Study Group
Surveillance of Invasive Streptococcus pneumoniae Infection in the Province of Quebec, Canada, from 1996 to 1998: Serotype Distribution, Antimicrobial Susceptibility, and Clinical Characteristics
J. Clin. Microbiol., February 1, 2001; 39(2): 733 - 737.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
P. N. Nyambi, A. Nádas, H. A. Mbah, S. Burda, C. Williams, M. K. Gorny, and S. Zolla-Pazner
Immunoreactivity of Intact Virions of Human Immunodeficiency Virus Type 1 (HIV-1) Reveals the Existence of Fewer HIV-1 Immunotypes than Genotypes
J. Virol., November 15, 2000; 74(22): 10670 - 10680.
[Abstract] [Full Text]

Home page
 PediatricsHome page
K. L. O'Brien, A. J. Swift, J. A. Winkelstein, M. Santosham, B. Stover, R. Luddy, J. E. Gootenberg, J. T. Nold, A. Eskenazi, S. J. Snader, et al.
Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 Among Infants With Sickle Cell Disease
Pediatrics, November 1, 2000; 106(5): 965 - 972.
[Abstract] [Full Text]

Home page
 CVIHome page
D. J. Sikkema, K. E. Friedman, B. Corsaro, A. Kimura, S. W. Hildreth, D. V. Madore, and S. A. Quataert
Relationship between Serum Bactericidal Activity and Serogroup-Specific Immunoglobulin G Concentration for Adults, Toddlers, and Infants Immunized with Neisseria meningitidis Serogroup C Vaccines
Clin. Vaccine Immunol., September 1, 2000; 7(5): 764 - 768.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
A. Nowak-Wegrzyn, J. A. Winkelstein, A. J. Swift, H. M. Lederman, and The Pneumococcal Conjugate Vaccine Study Group
Serum Opsonic Activity in Infants with Sickle-Cell Disease Immunized with Pneumococcal Polysaccharide Protein Conjugate Vaccine
Clin. Vaccine Immunol., September 1, 2000; 7(5): 788 - 793.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. D. Overturf, the Committee on Infectious Diseases, Committee on Infectious Diseases, 1999-2000, Ex-Officio, Liaisons, Consultant, and Staff
Technical Report: Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Polysaccharide Vaccines and Antibiotic Prophylaxis
Pediatrics, August 1, 2000; 106(2): 367 - 376.
[Abstract] [Full Text]

Home page
 CVIHome page
M. K. Park, D. E. Briles, and M. H. Nahm
A Latex Bead-Based Flow Cytometric Immunoassay Capable of Simultaneous Typing of Multiple Pneumococcal Serotypes (Multibead Assay)
Clin. Vaccine Immunol., May 1, 2000; 7(3): 486 - 489.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. I. Pelton;, O. S. Levine, C. A. Van Beneden, and B. Schwartz
Risk Factors for Invasive Pneumococcal Disease in Children: A Population-Based Case-Control Study in North America
Pediatrics, May 1, 2000; 105(5): 1172 - 1173.
[Full Text]

Home page
 Infect. Immun.Home page
R. S. Chu, T. McCool, N. S. Greenspan, J. R. Schreiber, and C. V. Harding
CpG Oligodeoxynucleotides Act as Adjuvants for Pneumococcal Polysaccharide-Protein Conjugate Vaccines and Enhance Antipolysaccharide Immunoglobulin G2a (IgG2a) and IgG3 Antibodies
Infect. Immun., March 1, 2000; 68(3): 1450 - 1456.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
T. L. McCool, C. V. Harding, N. S. Greenspan, and J. R. Schreiber
B- and T-Cell Immune Responses to Pneumococcal Conjugate Vaccines: Divergence between Carrier- and Polysaccharide-Specific Immunogenicity
Infect. Immun., September 1, 1999; 67(9): 4862 - 4869.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
J. D. Kellner, E. L. Ford-Jones, and and Members of the Toronto Child Care Centre Study
Streptococcus pneumoniae Carriage in Children Attending 59 Canadian Child Care Centers
Arch Pediatr Adolesc Med, May 1, 1999; 153(5): 495 - 502.
[Abstract] [Full Text] [PDF]